Australia markets closed

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.55-0.41 (-6.88%)
At close: 04:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 39.15M
Enterprise value 22.86M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.35
Price/book (mrq)2.54
Enterprise value/revenue 5.27
Enterprise value/EBITDA -1.81

Trading information

Stock price history

Beta (5Y monthly) 1.33
52-week change 3-52.16%
S&P500 52-week change 314.07%
52-week high 312.65
52-week low 35.55
50-day moving average 36.71
200-day moving average 38.87

Share statistics

Avg vol (3-month) 34.09k
Avg vol (10-day) 37.06k
Shares outstanding 56.32M
Implied shares outstanding 6N/A
Float 83.7M
% held by insiders 10.00%
% held by institutions 18.06%
Shares short (30 Dec 2021) 413.84k
Short ratio (30 Dec 2021) 42.73
Short % of float (30 Dec 2021) 4N/A
Short % of shares outstanding (30 Dec 2021) 40.22%
Shares short (prior month 29 Nov 2021) 41.55k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CHF.

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin -281.08%
Operating margin (ttm)-282.40%

Management effectiveness

Return on assets (ttm)-43.47%
Return on equity (ttm)-89.76%

Income statement

Revenue (ttm)4.64M
Revenue per share (ttm)0.87
Quarterly revenue growth (yoy)638.20%
Gross profit (ttm)-6.47M
EBITDA -13.37M
Net income avi to common (ttm)-13.05M
Diluted EPS (ttm)-2.66
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)15.49M
Total cash per share (mrq)2.72
Total debt (mrq)521.22k
Total debt/equity (mrq)3.91
Current ratio (mrq)5.33
Book value per share (mrq)2.35

Cash flow statement

Operating cash flow (ttm)-11.06M
Levered free cash flow (ttm)-6.19M